Abstract
We measured serum levels of syndecan-1 in patients with multiple myeloma (MM), solitary plasmocytoma and monoclonal gammopathy of undetermined significance (MGUS). We then studied serum syndecan-1 levels in MM patients stratified by the Durie-Salmon staging system and the correlation of syndecan-1 levels with well known independent prognostic factors of MM.
Vol. 89 No. 3 (2004): March, 2004 : Letters to the Editor
Published By
Ferrata Storti Foundation, Pavia, Italy
Statistics from Altmetric.com
